Anhui Fengyuan Pharmaceutical operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Anhui Fengyuan Pharmaceutical with three other
companies in this sector in China:
Chengdu Kanghong Pharmaceutical Group Co Ltd
sales of 2.92 billion Chinese Renmimbi [US$414.47 million]
of which 100%
was Pharmaceutical Manufacturing),
Sihuan Pharmaceutical Holdings Group Ltd
(2.92 billion Chinese Renmimbi [US$414.48 million]
of which 100%
was Pharmaceutical Prods), and
Jiuzhitang Company Limited
(3.12 billion Chinese Renmimbi [US$443.65 million]
of which 95%
was Pharmacuetical Industry).
During the year ended December of 2018, sales at
Anhui Fengyuan Pharmaceutical were 3.01 billion Chinese Renmimbi (US$428.11 million).
increase of 16.9%
versus 2017, when the company's sales were 2.58 billion Chinese Renmimbi.
This was the third consecutive year of growth at Anhui Fengyuan Pharmaceutical.
Sales of Medicine Manufacturing saw an increase
that was more than double the company's growth rate: sales were up
64.2% in 2018, from
1.01 billion Chinese Renmimbi to 1.66 billion Chinese Renmimbi.
Not all segments of Anhui Fengyuan Pharmaceutical experienced an increase in sales in 2018:
sales of Other Operations fell 15.9% to 56.62 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).
Anhui Fengyuan Pharmaceutical also experienced decreases in sales in
Medicine Retail Circulation (down 13.7% to 1.29 billion Chinese Renmimbi)